Jose Karam

21PUBLICATIONS
153CO-AUTHORS
Molecular targetsToxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Jun 20, 2026
5x-Multiplier Versus 3-Tier Model: A Pragmatic Randomized Clinical Trial for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery.

|Aug 25, 2025
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Yago Nieto, John F Ward, Wayne Hofstetter

|Jul 02, 2025
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Niki M Zacharias, Manuel Ozambela, Menuka Karki

|Jun 30, 2025
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol.

Brittany C Fields, Timothy E Newhook, Heather A Lillemoe

|Feb 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.

Sangeeta Goswami, Jianjun Gao, Sreyashi Basu

Pageof 4

Frequent Collaborators

6 joint publications

Matthew T Campbell

6 joint publications

Surena F Matin

4 joint publications

Pavlos Msaouel

4 joint publications

Jianjun Gao